NCT06911424

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

A Phase 3 Randomized, Multi-Center, Placebo-Controlled, Masked Study to Evaluate the Clinical Efficacy and Safety of Fusidic Acid 1% Viscous Topical Antibiotic Eye Drops for the Treatment of Suspected Bacterial Conjunctivitis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Baxis Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.

Conditions

• Bacterial Conjunctivitis

Interventions

Type	Name	Description
DRUG	Fusidic Acid 1%	Fusidic acid 1%
DRUG	Placebo	Placebo ophthalmic solution

Timeline

• Start date: 2025-03-21
• Primary completion: 2026-03-16
• Completion: 2026-03-23
• First posted: 2025-04-04
• Last updated: 2026-03-17

Locations

38 sites across 1 country: United States

Regulatory

• FDA-regulated drug study